* Note: Prices are in Million (M) USD.
Description:
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $60 M
Debt : $6 M
EBITDA : $-160 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health care
Industry: Biotechnology
Biotechnology detected → treating as non-Technology. 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 9 overlapping fiscal years (max 20).Average Free Cash Flow: $-67 M
Average Revenue: $19 M
Revenue Converted To Free Cash Flow (%): -360.2%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2025-12-31): $85 M
Revenue 5 Years Ago (2020-12-31): $14 M
Total Growth over 5 Years: 526.0%
5-Year Revenue CAGR (Historical): 44.3%
Forward 5-Year CAGR (Tapered): 22.2%
Since historical Revenue CAGR is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2025-12-31): $58 M
Share Count 5 Years Ago (2021-12-31): $28 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-3.86
Trailing 12-Month Earnings Per Share (EPS): $-3.83
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-3.86
- Latest/TTM EPS: $-3.83
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 6 valid ROE years (max 20).Average ROE: -29.9%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $9.94
52-Week Low: $2.24
Threshold Price (15% Above 52-Week Low): $2.57
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $507 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 1% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
Owners' Earnings (FCF/Share, latest positive annual) (2017-12-31): $0.13
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 11 points to above 4D Molecular Therapeutics Inc (FDMT) stock.
Fair Value PE 12, Industry Based PE 15, Growth Based PE 22.16, Risk-Free Anchored PE (25% MoS) 17.65. Based on these 4 values, average assigned is 16.70. The fair value of 4D Molecular Therapeutics Inc (FDMT) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
